Kiora Pharmaceuticals (KPRX) Total Non-Current Liabilities (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has 13 years of Total Non-Current Liabilities data on file, last reported at $4.5 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 10.91% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 10.91% YoY) and the FY2025 annual result came in at $4.5 million, down 4.68% from the prior year.
• Total Non-Current Liabilities held at $4.5 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $6.6 million in Q2 2025 to a low of $3.8 million in Q2 2022.
• A 5-year average of $4.9 million and a median of $4.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 40.75% — and 2023, when it surged 49.27%.
• Tracing KPRX's Total Non-Current Liabilities over 5 years: stood at $4.0 million in 2022, then jumped by 49.27% to $6.0 million in 2023, then decreased by 20.98% to $4.7 million in 2024, then decreased by 4.68% to $4.5 million in 2025, then declined by 0.02% to $4.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $4.5 million (Q1 2026), $4.5 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.